These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 26914222)

  • 41. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Zhao B; Zhao H
    Int J Cancer; 2018 Feb; 142(4):844-853. PubMed ID: 29023765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
    Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
    Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
    Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of hormone receptor status on the efficacy of HER2-targeted treatment.
    Zhao B; Zhao H; Zhao J
    Endocr Relat Cancer; 2018 Jun; 25(6):687-697. PubMed ID: 29739815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer.
    Ajmani GS; James TA; Kantor O; Wang CH; Yao KA
    Ann Surg Oncol; 2017 Oct; 24(11):3157-3166. PubMed ID: 28685357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
    Villacampa G; Matikas A; Oliveira M; Prat A; Pascual T; Papakonstantinou A
    Eur J Cancer; 2023 Sep; 190():112885. PubMed ID: 37142539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.
    Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
    Clin Cancer Res; 2023 Feb; 29(3):532-540. PubMed ID: 36449695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
    Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
    Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
    Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.